News - Heptares Therapeutics

Filter

Current filters:

Heptares Therapeutics

Popular Filters

Heptares appoints former GSK research head Tim Tasker as CMO

Heptares appoints former GSK research head Tim Tasker as CMO

10-01-2014

UK-based drug company Heptares Therapeutics has appointed Tim Tasker as chief medical officer and vice…

BoardroomHeptares TherapeuticsPharmaceuticalUK

Heptares gets first research milestone from Cubist

22-07-2013

UK GPCR drug discovery and development company Heptares Therapeutics says it has achieved the first research…

Cubist PharmaceuticalsFinancialHeptares TherapeuticsPharmaceuticalResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

MorphoSys and Heptares collaborate to develop antibody therapeutics targeting GPCRs

13-02-2013

German biotech firm MorphoSys (FSE: MOR) and closely-held UK-based GPCR drug discovery company Heptares…

BiotechnologyHeptares TherapeuticsMorphoSysResearch

Cubist partners with Heptares on new medicines targeting GPCRs; provides 2012 business update

08-01-2013

UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, has signed an…

ceftolozaneCubist PharmaceuticalsFinancialGenito-urinaryHeptares TherapeuticsLicensingPharmaceuticalResearchtazobactam

Shire signs $190 million deal for preclinical CNS drug

21-03-2012

Ireland-headquartered drugmaker Shire (LSE: SHP) has exercised its exclusive option to license a novel…

Heptares TherapeuticsLicensingNeurologicalPharmaceuticalShire

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront

31-05-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year…

AstraZenecaDermatologicalsHeptares TherapeuticsLicensingNeurologicalPharmaceuticalResearch

Shire gets exclusive option for Heptares A2A program for CNS diseases

10-05-2011

Closely-held UK-based drug discovery firm Heptares Therapeutics says it has signed an exclusive option…

Heptares TherapeuticsLicensingNeurologicalPharmaceuticalShire

Back to top